Akers Biosciences Issued European Patent Protection for Breath Ketone Detector
November 10 2016 - 7:00AM
Marketwired
Akers Biosciences Issued European Patent Protection for Breath
Ketone Detector
THOROFARE, NJ-(Marketwired - Nov 10, 2016) - Akers Biosciences,
Inc. (NASDAQ: AKER) (AIM: AKR), ("Akers Bio" or the "Company"), a
developer of rapid health information technologies, announces that
the European Patent Office has issued a patent covering the
Company's Breath Ketone Detector (EP 2684025) (the "Patent"), the
Company's single-use, non-invasive, breath device to rapidly
monitor ketone levels. Akers Bio was granted U.S. patent protection
covering the same technology in 2014.
The Patent protects both the methods and devices related to the
Breath Ketone Detector. The Breath Ketone Detector was developed
utilizing Akers Bio's proprietary MPC Biosensor Technology platform
which facilitates the rapid identification of medical or metabolic
conditions through biomarkers in exhaled breath condensate.
Ketones are acids which have the potential to build up in the
body causing a condition referred to as ketosis. An extreme form of
this condition is a life-threatening medical emergency called
ketoacidosis. At-risk populations for this severe form of ketosis
include those with diabetes, and people who subscribe to
restrictive ketogenic diets for epilepsy management or to obtain
aggressive weight loss results.
The Company's Breath Ketone Detector technology is a
first-in-class device that detects the presence of ketones in a
person's breath condensate. Ketones are present in the blood and
breath before they can be detected in urine, making this a highly
desirable screening method - both in terms of cost and comfort -
when compared to invasive blood tests.
Akers Bio has developed three applications to date for the
Breath Ketone Detector which will be marketed as BreathScan DKA -
for real-time monitoring and diagnostic use by diabetics (subject
to regulatory clearance); BreathScan KetoChek - part of the Akers
Wellness line, enabling users to track and monitor their ketone
levels in conjunction with a quantitative reading device connected
to a smartphone app; and METRON - a consumer-focused qualitative
version from the Akers Wellness line aimed at people interested
weight loss management and fitness.
"Having robust protection over our intellectual property is of
paramount importance for safeguarding the value of our inventions.
We are delighted to have been awarded this Patent which offers
broad coverage and has been some years in the making," said Raymond
F. Akers, Jr., Ph.D., Co-founder and Chief Scientific Director.
"Achieving patent protection in the key territories of the U.S.
and Europe is very significant for the Breath Ketone Detector
technology because of the enormous target markets of diabetes and
health and wellness that we are positioning the tests for,"
continued Dr. Akers.
"The technology has a large number of potential mass-market
applications, including within health and wellness, but in
particular, we believe the ability to help Type 1 and some Type 2
diabetics monitor their ketone levels in a non-invasive, convenient
format will be a significant advancement in the management of a
disease that affects hundreds of millions of people worldwide,"
added Dr. Akers.
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information: Akers Biosciences, Inc. Raymond F. Akers,
Jr. PhD Co-founder and Chief Scientific Director Tel. +1 856 848
8698 Taglich Brothers, Inc. (Investor Relations) Chris Schreiber
Tel. +1 917 445 6207 Email: cs@taglichbrothers.com finnCap (UK
Nominated Adviser and Broker) Adrian Hargrave / Scott Mathieson
(Corporate Finance) Steve Norcross (Broking) Tel. +44 (0)20 7220
0500 Vigo Communications (Global Public Relations) Ben Simons /
Fiona Henson Tel. +44 (0)20 7830 9700 Email:
akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024